Interstitial lung disease in systemic sclerosis: current and future treatment

Area of Science:

• Rheumatology
• Pulmonology
• Internal Medicine

Background:

• Systemic sclerosis (SSc) is a severe connective tissue disease with high fatality rates.
• Vascular damage, inflammation, and fibrosis characterize SSc, affecting skin and internal organs.
• Interstitial lung disease (ILD) is a frequent and debilitating complication of SSc, leading to a poor prognosis.

Purpose of the Study:

• To provide a comprehensive overview of SSc-ILD.
• To summarize current knowledge on classification, pathogenesis, diagnosis, and prognosis.
• To discuss current and future therapeutic strategies for SSc-ILD.

Main Methods:

• Literature review and synthesis of existing research on SSc-ILD.
• Analysis of diagnostic criteria, including lung function tests and high-resolution computed tomography (HRCT).
• Evaluation of prognostic factors and survival data.

Main Results:

• ILD is the leading cause of death in SSc patients.
• Early detection of pulmonary involvement is critical for effective management.
• Management of SSc-ILD remains a significant clinical challenge.

Conclusions:

• SSc-ILD requires a multidisciplinary approach for optimal patient care.
• Advances in understanding pathogenesis are paving the way for novel treatments.
• Continued research is essential to improve outcomes for SSc-ILD patients.